Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation
Pfizer shares hit a 52-week high of $28.30 in New York Tuesday, lifted by recent drug pipeline updates and strong fourth-quarter sales. The company reported Q4 revenue of $17.56 billion and reaffirmed 2026 guidance. Some analysts remain cautious, with Acquirer’s Multiple valuing shares at $14–$15. Recent trial data showed positive results for Talzenna in prostate cancer and atirmociclib in breast cancer.